Reema Ishteiwy
Newark, NJNPI 1003444340
Payments from drug & device makers
Across 70 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$545
- AstraZeneca$467
- Daiichi Sankyo Inc.$200
- Novartis$68
- Incyte Corporation$53
- Pfizer$52
- plus $359 from 14 others
What the payments were for
- Food & beverage$1,64494%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 26 | $545 |
| AstraZeneca | 10 | $467 |
| Daiichi Sankyo Inc. | 9 | $200 |
| Novartis | 3 | $68 |
| Incyte Corporation | 3 | $53 |
| Pfizer | 2 | $52 |
| Lilly USA, LLC | 2 | $48 |
| Stemline Therapeutics Inc. | 2 | $46 |
| Mirati Therapeutics, Inc. | 2 | $38 |
| Novocure Inc. | 1 | $28 |
| Elekta, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Seagen Inc. | 1 | $21 |
| Amgen | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Blue Earth Diagnostics | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $18 |
| Bayer | 1 | $16 |
| Beigene USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.